ImmunoGen Cancer Patent Still Valid After Phigenix’s Dispute

Eldora Ellison, Ph.D., is quoted in Bloomberg BNA’s, “Immunogen Cancer Patent Still Valid After Phigenix’s Dispute,” discussing the Patent Trial and Appeal Board’s (PTAB) final written decision to uphold the validity of ImmunoGen, Inc.’s U.S. Patent Number 8,337,856 B2 for its breast-cancer treatment drug Kadcyla.

Dr. Ellison remarked, “Our team was very pleased that the PTAB upheld this patent covering Kadcyla, which is an innovative drug that has changed the lives of breast cancer patients.”

Sterne Kessler represented ImmunoGen in this matter. The team is led by Dr. Ellison and includes, Eric Steffe, Olga Partington, Ph.D., Cynthia DeRenzo, Ph.D., David Roadcap, Ph.D., and Christopher Gallo, Ph.D.